631 related articles for article (PubMed ID: 28202319)
1. The Women's EMPOWER Survey: Women's Knowledge and Awareness of Treatment Options for Vulvar and Vaginal Atrophy Remains Inadequate.
Krychman M; Graham S; Bernick B; Mirkin S; Kingsberg SA
J Sex Med; 2017 Mar; 14(3):425-433. PubMed ID: 28202319
[TBL] [Abstract][Full Text] [Related]
2. The Women's EMPOWER Survey: Identifying Women's Perceptions on Vulvar and Vaginal Atrophy and Its Treatment.
Kingsberg SA; Krychman M; Graham S; Bernick B; Mirkin S
J Sex Med; 2017 Mar; 14(3):413-424. PubMed ID: 28202320
[TBL] [Abstract][Full Text] [Related]
3. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey.
Kingsberg SA; Wysocki S; Magnus L; Krychman ML
J Sex Med; 2013 Jul; 10(7):1790-9. PubMed ID: 23679050
[TBL] [Abstract][Full Text] [Related]
4. Perceptions of dyspareunia in postmenopausal women with vulvar and vaginal atrophy: findings from the REVIVE survey.
Freedman MA
Womens Health (Lond); 2014 Jul; 10(4):445-54. PubMed ID: 25259904
[TBL] [Abstract][Full Text] [Related]
5. Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVE Survey.
Nappi RE; Palacios S; Panay N; Particco M; Krychman ML
Climacteric; 2016 Apr; 19(2):188-97. PubMed ID: 26581580
[TBL] [Abstract][Full Text] [Related]
6. The REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey in Europe: Country-specific comparisons of postmenopausal women's perceptions, experiences and needs.
Nappi RE; Palacios S; Particco M; Panay N
Maturitas; 2016 Sep; 91():81-90. PubMed ID: 27451325
[TBL] [Abstract][Full Text] [Related]
7. Helping Women Understand Treatment Options for Vulvar and Vaginal Atrophy.
Parks DM; Levine J
Nurs Womens Health; 2015; 19(4):298-312. PubMed ID: 26264795
[TBL] [Abstract][Full Text] [Related]
8. WISDOM survey: attitudes and behaviors of physicians toward vulvar and vaginal atrophy (VVA) treatment in women including those with breast cancer history.
Kingsberg SA; Larkin L; Krychman M; Parish SJ; Bernick B; Mirkin S
Menopause; 2019 Feb; 26(2):124-131. PubMed ID: 30130293
[TBL] [Abstract][Full Text] [Related]
9. Attitudes and perceptions towards vulvar and vaginal atrophy in Italian post-menopausal women: Evidence from the European REVIVE survey.
Nappi RE; Particco M; Biglia N; Cagnacci A; Di Carlo C; Luisi S; Paoletti AM
Maturitas; 2016 Sep; 91():74-80. PubMed ID: 27451324
[TBL] [Abstract][Full Text] [Related]
10. The Association Between Vulvovaginal Atrophy Symptoms and Quality of Life Among Postmenopausal Women in the United States and Western Europe.
DiBonaventura M; Luo X; Moffatt M; Bushmakin AG; Kumar M; Bobula J
J Womens Health (Larchmt); 2015 Sep; 24(9):713-22. PubMed ID: 26199981
[TBL] [Abstract][Full Text] [Related]
11. Macro-regional variation in attitudes toward and experiences of vulvar and vaginal atrophy among Italian post-menopausal women: a post hoc analysis of REVIVE survey data.
Nappi RE; Particco M; Biglia N; Cagnacci A; Di Carlo C; Luisi S; Paoletti AM
Gynecol Endocrinol; 2017 May; 33(5):389-394. PubMed ID: 28277131
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and impact of vaginal symptoms among postmenopausal women.
Santoro N; Komi J
J Sex Med; 2009 Aug; 6(8):2133-42. PubMed ID: 19493278
[TBL] [Abstract][Full Text] [Related]
13. Estradiol softgel inserts for the treatment of VVA symptoms: an expert opinion.
Liu JH; Bernick B; Mirkin S
Expert Opin Drug Deliv; 2020 Nov; 17(11):1573-1581. PubMed ID: 32877254
[TBL] [Abstract][Full Text] [Related]
14. The effect of vulvovaginal atrophy on women's quality of life from an Italian cohort of the EVES study.
Nappi RE; Di Carlo C; Becorpi AM; Gambacciani M; De Seta F; Ribaldone R; Benedetto C; Paoletti AM;
J Obstet Gynaecol; 2020 May; 40(4):512-519. PubMed ID: 31496326
[TBL] [Abstract][Full Text] [Related]
15. Management of Vaginal Atrophy: Implications from the REVIVE Survey.
Wysocki S; Kingsberg S; Krychman M
Clin Med Insights Reprod Health; 2014; 8():23-30. PubMed ID: 24987271
[TBL] [Abstract][Full Text] [Related]
16. The American-European difference in vulvar and vaginal atrophy views: a lesson from the REVIVE Survey.
Nappi RE; Krychman ML
Climacteric; 2016 Jun; 19(3):252-5. PubMed ID: 27094975
[TBL] [Abstract][Full Text] [Related]
17. Vulvar and vaginal atrophy as viewed by the Spanish REVIVE participants: symptoms, management and treatment perceptions.
Palacios S; Cancelo MJ; Castelo Branco C; Llaneza P; Molero F; Borrego RS
Climacteric; 2017 Feb; 20(1):55-61. PubMed ID: 28042734
[TBL] [Abstract][Full Text] [Related]
18. Iranian postmenopausal women's experiences of treatment of symptomatic vulvovaginal atrophy.
Fooladi E; Deldar M; Mohammadzadeh F; Ahmadnia E; Khani S; Ghanbari Z
Climacteric; 2017 Feb; 20(1):67-71. PubMed ID: 28064523
[TBL] [Abstract][Full Text] [Related]
19. Symptoms, attitudes and treatment perceptions of vulvo-vaginal atrophy in UK postmenopausal women: Results from the REVIVE-EU study.
Domoney C; Short H; Particco M; Panay N
Post Reprod Health; 2020 Jun; 26(2):101-109. PubMed ID: 32627698
[TBL] [Abstract][Full Text] [Related]
20. The CLOSER (CLarifying Vaginal Atrophy's Impact On SEx and Relationships) survey: implications of vaginal discomfort in postmenopausal women and in male partners.
Nappi RE; Kingsberg S; Maamari R; Simon J
J Sex Med; 2013 Sep; 10(9):2232-41. PubMed ID: 23809691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
